Cancer Research AACR Conference on Molecular Diagnostics - 2008  Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 32, 1397-1403, July 1, 1972]
© 1972 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Munson, A. E.
Right arrow Articles by Wampler, G. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Munson, A. E.
Right arrow Articles by Wampler, G. L.

Effect of Tilorone Hydrochloride and Congeners on Reticuloendothelial System, Tumors, and the Immune Response

Albert E. Munson, Judith A. Munson, William Regelson and Galen L. Wampler

Division of Medical Oncology, Medical College of Virginia, Health Sciences Division, Virginia Commonwealth University, Richmond, Virginia 23219

Five analogs of Tilorone hydrochloride demonstrated varying degrees of activity on the following host defense mechanisms: (a) antitumor activity to Ehrlich carcinoma solid tumor and Friend leukemia virus, (b) in vivo antibacterial activity to Staphylococcus aureus, (c) functional activity of the reticuloendothelial system, and (d) enhancement of the 19 S immunological response.

Bis(3-diethylaminopropyl)fluoranthene-3,9-dicarboxylate dihydrochloride and 2,7-bis(2-diethylaminoacetyl)fluorene dihydrochloride inhibited Ehrlich solid tumor development up to 93%. 2,7-Bis(2-diethylaminoacetyl)fluorene dihydrochloride and 2,7-bis(2-dimethylaminoethoxy)fluoren-9-one dihydrochloride inhibited Friend leukemia virus splenomegaly 94 and 70%, respectively, during the proliferative phase of the disease. 2,7-Bis(2-diethylaminoacetyl)fluorene dihydrochloride and 2,6-bis(N-3-dibutylaminopropylsulfamoyl)anthraquinone dihydrochloride protected mice from 2 x 108 S. aureus, provided that the drugs were administered 24 hr before the bacterial inoculation.

The most potent stimulus of reticuloendothelial system activity was 2,6-bis(N-3-dibutylaminopropylsulfamoyl)-anthraquinone dihydrochloride, which enhances the vascular clearance of colloidal carbon up to 118%, as contrasted to bis(3-diethylaminopropyl)fluoranthene-3,9-dicarboxylate dihydrochloride, which decreased the phagocytic index 29%. Tilorone hydrochloride and 2,7-bis(2-diethylaminoacetyl)-fluorene dihydrochloride markedly enhanced the 19 S immune response, as manifested in 288 and 216 plaque-forming cells/106 nucleated spleen cells on peak day, respectively, as compared to 162 for the control mice.

Tilorone hydrochloride and related congeners represent a new series of compounds with a multiplicity of host-mediated biological activities.

Received 12/30/71. Accepted 3/23/72.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1972 by the American Association for Cancer Research.